Patients' perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis

被引:14
|
作者
Casellas, Francesc [1 ]
Vicens, Daniel Ginard [2 ]
Riestra Menendez, Sabino [3 ]
Alfaro Oliver, Noelia [4 ]
机构
[1] Hosp Univ Vall dHebron, Ciberehd, Crohn Colitis Care Unit, Barcelona 08035, Spain
[2] Hosp Univ Son Espases, Dept Gastroenterol, Palma de Mallorca 07120, Islas Baleares, Spain
[3] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo 33006, Asturias, Spain
[4] Adv Res Tech Hlth Serv TAISS, Madrid 28034, Spain
来源
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷 / 09期
关键词
Ulcerative colitis; Management of the disease; Treatment of the disease; Quality of life; Patient satisfaction; INFLAMMATORY-BOWEL-DISEASE; HEALTH-CARE; SATISFACTION; PERSPECTIVE; COPENHAGEN;
D O I
10.1016/j.crohns.2014.02.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To establish the perceptions, attitudes, experiences, and satisfaction with clinical management of ulcerative colitis (UC) patients, particularly in aspects related to treatment. Methods: A qualitative, descriptive, exploratory study. A discussion group was performed in patients who were in remission according to the criteria of the Mayo index, who had never taken biologics or corticosteroids in the past year. They were selected by: course (mild/moderate), time since onset (under 5 years/5 to 9 years/10 years or more), follow-up area (primary care [PC]-hospital/PC-specialist care/hospital), treatment (yes/no), UC care unit (yes/no), belongs to patient associations (yes/no) and sex. A descriptive-interpretative content analysis was performed to detect emerging categories, providing them with an explanatory framework. Results: Diagnostic delay was detected due to lack of clinical suspicion from PC and delayed diagnostic tests. For follow-up, patients prefer care on demand, channeled through remote care, which helps to resolve questions, problems with treatment, or when a relapse occurs, minimizing visits to the hospital. They demand more information, both about UC and treatment. The expectations about treatments are limited, so they mainly requested efficacy and safety. Conclusion: The results suggest the importance of developing strategies to facilitate care on demand and remote care, and to investigate on effective and safe treatments to minimize the detriment to quality of life of patients. These strategies should guarantee fast care and, together with safe and effective treatments, optimize the management of UC patients. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1097 / 1107
页数:11
相关论文
共 50 条
  • [21] International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
    Caron, Benedicte
    Jairath, Vipul
    D'Amico, Ferdinando
    Al Awadhi, Sameer
    Dignass, Axel
    Hart, Ailsa L.
    Kobayashi, Taku
    Kotze, Paulo Gustavo
    Magro, Fernando
    Siegmund, Britta
    Paridaens, Kristine
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    MEDICINA-LITHUANIA, 2023, 59 (01):
  • [22] Evaluating induction and maintenance treatment with MMX mesalazine for patients with mild-to-moderate ulcerative colitis
    Solomon, D.
    Abhyankar, B.
    Barrett, K.
    Karlstadt, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A90 - A90
  • [23] Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
    Dignass, Axel U.
    Paridaens, Kristine
    Al Awadhi, Sameer
    Begun, Jakob
    Cheon, Jae Hee
    Fullarton, John R.
    Louis, Edouard
    Magro, Fernando
    Ricardo Marquez, Juan
    Moschen, Alexander R.
    Narula, Neeraj
    Rydzewska, Grazyna
    Travis, Simon P. L.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (04) : 424 - 431
  • [24] BalsalazideA Review of its Therapeutic Use in Mild-to-Moderate Ulcerative Colitis
    Richard B. R. Muijsers
    Karen L. Goa
    Drugs, 2002, 62 : 1689 - 1705
  • [25] Balsalazide - A review of its therapeutic use in mild-to-moderate ulcerative colitis
    Muijsers, RBR
    Goa, KL
    DRUGS, 2002, 62 (11) : 1689 - 1705
  • [26] Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis
    Ma, Christopher
    Jeyarajah, Jenny
    Guizzetti, Leonardo
    Parker, Claire E.
    Singh, Siddharth
    Dulai, Parambir S.
    D'Haens, Geert R.
    Sandborn, William J.
    Feagan, Brian G.
    Jairath, Vipul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : 447 - +
  • [27] The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
    Cheon, Jae Hee
    Paridaens, Kristine
    Al Awadhi, Sameer
    Begun, Jakob
    Fullarton, John R.
    Louis, Edouard
    Magro, Fernando
    Marquez, Juan Ricardo
    Moschen, Alexander R.
    Narula, Neeraj
    Rydzewska, Grazyna
    Dignass, Axel U.
    Travis, Simon Pl
    INTESTINAL RESEARCH, 2022, : 161 - 167
  • [28] AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis (vol 156, pg 769, 2019)
    Singh, S.
    Feuerstein, J. D.
    Binion, D. G.
    GASTROENTEROLOGY, 2019, 157 (03) : 903 - 903
  • [29] Gut microbiome diversity in acute severe colitis is distinct from mild-to-moderate ulcerative colitis
    Kedia, S.
    Ghosh, T. S.
    Das, B.
    Jain, S.
    Bopanna, S.
    Makharia, G.
    Travis, S.
    Ahuja, V.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S114 - S115
  • [30] Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis
    Olmstead, Jill
    JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2010, 22 (11): : 586 - 592